Abstract Presentations

There are a total of eight presentation groups. Groups 1–4 will take place from 10:10 a.m. to 11:50 a.m., and Groups 5–8 from 1:30 p.m. to 3:10 p.m.

Each presentation slot is 20 minutes, with 12–15 minutes allotted for presentations and approximately 5 minutes for questions.

Group One- PDD 2006


Time	Name	Title
10:10-10:30 a.m.	Te-Lien Ku	Designing With, Not For: Co-Designing a Community Pharmacy-Based Service Framework to Support Care Partners of People Living with Dementia
10:30-10:50 a.m.	Minghui Deng	Mapping Patient Information Requests in Community Pharmacy Practice: Comparing Frequency and Type Across Diverse Care Settings
10:50-11:10 a.m.	Christina Ojo	Payor Perspectives on Implementing Community Pharmacy-Delivered Transitions of Care Services in Indiana
11:10-11:30 a.m.	Mercy Nwaodu	The Access Gap: Pharmacy Deserts and Medication Adherence in Type 2 Diabetes
11:30- 11:50 a.m.	Juan Diego Viracacha Suarez	Beyond Dispensing: Public Health Service Delivery in Keystone Pharmacies in Indiana


Time	Name	Title
10:10-10:30 a.m.	Chi-Han Cheng	Target Trial Emulation of GLP-1 Receptor Agonists and Reproductive Outcomes in Polycystic Ovary Syndrome
10:30-10:50 a.m.	Finey Chernporn Navanu	Out-of-Pocket Burden and Payment Patterns for GLP-1 Therapies in 2023: A National MEPS Analysis
10:50-11:10 a.m.	Tzu Wang	Persistence in GLP-1–Based Therapy Among Adults with Obesity and Type 2 Diabetes: A Narrative Review
11:10- 11:30 a.m.	Nha Tran	Intention to Discuss Deprescribing with a Clinician among Overtreated Older Adults with Type 2 Diabetes: A Structural Equation Modeling Study


Time	Name	Title
10:10-10:30 a.m.	Enas Yehya	Assessment of Individual Entrepreneurial Orientation and Innovation Decision-Making Among PharmD Students in the United States : An Exploratory Sequential Mixed Methods Study
10:30-10:50 a.m.	Rahmeh Qandil	The Effect of Mandatory Switching from Stelara® to a Biosimilar: Possible Unintended Consequences of Different Manufacturer Patient Savings Programs
10:50-11:10 a.m.	Felix Ting	Evaluating the Cumulative Effectiveness of Annual Comprehensive Medication Reviews on Medication Adherence in Medicare Part D Beneficiaries
11:10-11:30 a.m.	Chun-Tse Hung	Medication Reviews and Pharmacist-involved Interventions on Anticholinergic Burden Among U.S. Community-Dwelling Older Adults: A Narrative Review
11:30- 11:50 a.m.	Pearl Craig	Life Satisfaction as a Broader Patient-Reported Outcome: A Cross-National Study of Health and Non-Health Factors


Time	Name	Title
10:10-10:30 a.m.	Austin Geer	Evaluation of a Remote Pharmacist-Led Monitoring Model for Oral Anticancer Agents: A Narrative Review
10:30-10:50 a.m.	Bukky Tikare	Optimizing Medication Use in Breast Cancer Survivors through a Patient-Centered Survivorship Care Plan: A Mixed Methods Study
10:50-11:10 a.m.	Fiza Ayub	Exploratory Interview Study on the Role of Pharmacists in the Management of Stages II/ III Breast Cancer Patients
11:10-11:30 a.m.	Adebowale Adeyemi	From Best Supportive Care to Triple-Combination Therapy: A Cost-Effectiveness Analysis of First-Line Treatment Strategies for MSI-H/dMMR Metastatic Colorectal Cancer" and presents preliminary findings from an ongoing decision-analytic cost-effectiveness study
11:30- 11:50 a.m.	Pegah Farrokhi	Comparative Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses


Time	Name	Title
1:30-1:50 p.m.	Bryan Kendall	Battlefield Acupuncture and Chronic Lower Back Pain in an Assisted Living Setting
1:50-2:10 p.m.	Muhammad Musa	Behavioral determinants of pre-treatment DPYD testing use among U.S. medical oncologists: An explanatory sequential mixed methods study
2:10-2:30 p.m.	Maisa Nazzal	Longitudinal Changes in Social Support and Health Outcomes Among Older Adults With Cancer: A Narrative Review
2:30-2:50 p.m.	Mohamad Ismail	Culturally Relevant Determinants of Oral Anticancer Agent Self-Management Among Arab American Individuals: An Exploratory Sequential Mixed Methods Study
2:50- 3:10 p.m.	Shruti Ayyalasomayajula	Subcutaneous vs Intravenous Amivantamab in First-Line EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Budget


Time	Name	Title
1:30-1:50 p.m.	Camilo Alvarez-Nunez	Enhancing Access and Adherence of Continuous Glucose Monitoring (CGM) in Patients with Type 2 Diabetes Mellitus (T2DM)
1:50-2:10 p.m.	Tyler McCarthy	Health System Ambulatory Care Pharmacist Information Ecosystem Study
2:10-2:30 p.m.	Mohammad Alnuman	Real-world Changes in Weight and Blood Pressure During and After Anti Obesity Medication Use
2:30-2:50 p.m.	Sodam Kim	From Patient Advisory Board Engagement to Real-World Evidence in ATTR-CM
2:50- 3:10 p.m.	Taylor Huang	Treatment Pattern and Healthcare Resource Utilization of Pediatric Patients with Atopic Dermatitis in the United States


Time	Name	Title
1:30-1:50 p.m.	Lubna Hassan	Early Detection of Workflow Interruption in Pharmacy EHRs: A Human Factors and Machine Learning Approach
1:50-2:10 p.m.	Fatima Ibrahim	Nationwide Analysis of Pharmacists’ Most Common Work Activities
2:10-2:30 p.m.	Isra Guntane	Aligning Pharmacists’ 1st and 2nd Most Preferred Work Activities with Factors of Success in Practice
2:30-2:50 p.m.	Emma Polucha	Exploring Pharmacists’ Experiences with Workforce Changes and Evolving Roles: A Focus Group Study
2:50- 3:10 p.m.	Mushtakh Mohammaed	Focus Group Study Exploring Pharmacists’ Perspectives on their Roles and Workplace


Time	Name	Title
1:30-1:50 p.m.	Hao-Ping Chiang	Understanding Factors Influencing the Concomitant Use of Herbal Supplements and Prescription Medications
1:50-2:10 p.m.	Yifan Zheng	Beyond the ASCVD Checkbox: A Hierarchy of Antihypertensive Fill-History Representations as Cardiovascular Digital Prognostic Markers
2:10-2:30 p.m.	Michael Pham	Response Option Interpretation to Inform PRO Measure Designs: A Multinational Study
2:30-2:50 p.m.	Annika Pickard	Addressing Challenges in Health State Valuation: Does Health Literacy Matter?
2:50- 3:10 p.m.	Azeez Aina	Prevalence of Alzheimer’s Disease and Related Dementia Modifiable Risk Factors Prior to Cognitive Impairment: Preliminary Analysis of the National Alzheimer’s Coordination Center Datasets (2005-2025)